| Literature DB >> 28408440 |
Bernadette Thomas1,2, Kunihiro Matsushita3, Kalkidan Hassen Abate4, Ziyad Al-Aly5, Johan Ärnlöv6,7, Kei Asayama8, Robert Atkins9, Alaa Badawi10,11, Shoshana H Ballew3, Amitava Banerjee12, Lars Barregård13, Elizabeth Barrett-Connor14, Sanjay Basu15, Aminu K Bello16, Isabela Bensenor17, Jaclyn Bergstrom14, Boris Bikbov18, Christopher Blosser2, Hermann Brenner19, Juan-Jesus Carrero20, Steve Chadban21,22,23, Massimo Cirillo24, Monica Cortinovis25, Karen Courville25, Lalit Dandona26,27, Rakhi Dandona26,27, Kara Estep26, João Fernandes28, Florian Fischer29, Caroline Fox30, Ron T Gansevoort31, Philimon N Gona32, Orlando M Gutierrez33, Samer Hamidi34, Sarah Wulf Hanson26, Jonathan Himmelfarb2, Simerjot K Jassal35, Sun Ha Jee36, Vivekanand Jha37,38, Aida Jimenez-Corona39,40, Jost B Jonas41, Andre Pascal Kengne42,43, Yousef Khader44, Young-Ho Khang45, Yun Jin Kim46, Barbara Klein47, Ronald Klein47, Yoshihiro Kokubo48, Dhaval Kolte49, Kristine Lee50, Andrew S Levey51, Yongmei Li52, Paulo Lotufo17, Hassan Magdy Abd El Razek53, Walter Mendoza54, Hirohito Metoki55, Yejin Mok36, Isao Muraki56, Paul M Muntner57, Hiroyuki Noda58, Takayoshi Ohkubo8, Alberto Ortiz59, Norberto Perico25, Kevan Polkinghorne60,61, Rajaa Al-Radaddi62, Giuseppe Remuzzi25,63,64, Gregory Roth26, Dietrich Rothenbacher65, Michihiro Satoh55, Kai-Uwe Saum19, Monika Sawhney66, Ben Schöttker19,67, Anoop Shankar68, Michael Shlipak52, Diego Augusto Santos Silva69, Hideaki Toyoshima70, Kingsley Ukwaja71, Mitsumasa Umesawa72, Stein Emil Vollset73,74,26, David G Warnock75, Andrea Werdecker76, Kazumasa Yamagishi77, Yuichiro Yano78, Naohiro Yonemoto79, Maysaa El Sayed Zaki53, Mohsen Naghavi26, Mohammad H Forouzanfar26, Christopher J L Murray26, Josef Coresh3, Theo Vos26.
Abstract
The burden of premature death and health loss from ESRD is well described. Less is known regarding the burden of cardiovascular disease attributable to reduced GFR. We estimated the prevalence of reduced GFR categories 3, 4, and 5 (not on RRT) for 188 countries at six time points from 1990 to 2013. Relative risks of cardiovascular outcomes by three categories of reduced GFR were calculated by pooled random effects meta-analysis. Results are presented as deaths for outcomes of cardiovascular disease and ESRD and as disability-adjusted life years for outcomes of cardiovascular disease, GFR categories 3, 4, and 5, and ESRD. In 2013, reduced GFR was associated with 4% of deaths worldwide, or 2.2 million deaths (95% uncertainty interval [95% UI], 2.0 to 2.4 million). More than half of these attributable deaths were cardiovascular deaths (1.2 million; 95% UI, 1.1 to 1.4 million), whereas 0.96 million (95% UI, 0.81 to 1.0 million) were ESRD-related deaths. Compared with metabolic risk factors, reduced GFR ranked below high systolic BP, high body mass index, and high fasting plasma glucose, and similarly with high total cholesterol as a risk factor for disability-adjusted life years in both developed and developing world regions. In conclusion, by 2013, cardiovascular deaths attributed to reduced GFR outnumbered ESRD deaths throughout the world. Studies are needed to evaluate the benefit of early detection of CKD and treatment to decrease these deaths.Entities:
Keywords: Epidemiology and outcomes; cardiovascular disease; chronic dialysis; chronic kidney disease; end stage kidney disease
Mesh：
Year: 2017 PMID： 28408440 PMCID： PMC5491277 DOI： 10.1681/ASN.2016050562
Source DB: PubMed Journal: J Am Soc Nephrol ISSN： 1046-6673 Impact factor: 10.121